Urine Samples Could Help Predict Heart Attacks, Breast and Prostate Cancer, Study Claims


This excerpt post is based on this original article.

A new study shows that about 90% of volunteers who donated a urine sample to the Oregon Institute of Science and Medicine had specific metabolic profiles for three distinct conditions: cardiac events, and breast and prostate cancer. All of these urinary patterns appeared before the diseases’ subsequent symptoms and medical diagnoses.

The study titled, “Metabolic Profiling with Magnetic Resonance Mass Spectrometry and a Human Urine Bank: Profiles for Aging, Sex, Heart Disease, Breast Cancer and Prostate Cancer,” was published in the Journal of American Physicians and Surgeons.

The concept appeared in the late 1960s and continued throughout the ’70s, based largely on the work of Arthur Robinson. Robinson discovered the existence of metabolic profiles for many conditions, including multiple sclerosis and Huntington’s disease. Unfortunately, due to limited resources at the time, progress on the research stalled.

Nowadays, the Oregon Institute of Science and Medicine has a urine sample bank to which 5,000 volunteers periodically contribute urine specimens and medical histories. As time goes by, samples from patients who develop a medical event of interest accumulate. These are then quantitatively analyzed by magnetic resonance mass spectrometry (MRMS).

MRMS simultaneously quantifies over 800 molecular urinary components of human metabolic origin. Using this technique, researchers examined profiles for aging, sex, heart disease, breast cancer, and prostate cancer.

The research encouragingly revealed a 99.99% chance that the team identified a profile predictive of a subsequent cardiac event. In the case of breast or prostate cancer, there’s a 94% and 97% probability, respectively, that patterns predictive of disease have been identified.


Quantitive health monitoring and evaluating clinical interventions can be facilitated by an individual patient’s urine samples over time, the researchers noted.

Researchers hope to develop an affordable $5 test that measures common metabolic products. Such profiles could have strong potential for preventive, diagnostic, and therapeutic medicine. Currently, MRMS is solely a research technique.

September 2017 Prostate Cancer Awareness Month — Bling your Underwear

Doctors can’t always give their patients round the clock attention and care. This is why  the talented nurses that work day in and day out with the patients, before, during and after prostate cancer surgery are so important. We can’t praise these men and women enough!  They are on the front lines of patients recovery. That is why it’s so very important that these doctors and nurses keep the patients upbeat and happy. As we all know happy and upbeat patients are more engaged in their recovery.

This year for Prostate Cancer Awareness month, the Nurses of the Prostate Cancer Surgery Department created this great patient contest to promote Prostate Cancer Awareness Month. “BLING YOUR UNDERWEAR!”

Below are just some of the fun entries! Join us in honoring in the Men and Women Nurses who handle the day in and out care of Prostate Cancer Patients. Our Hats are off to you!!! We thank you for everything you do! (Ps. also a belated happy birthday to our founder Dr. Vipul Patel)



Location. Location. Location.

Above: Map of all the locations Dr. Patel has either taught or performed surgery.
Below: excerpts from studies and articles found here.

According to a new analysis of data from between 1980 and 2014, the trends and differences in cancer mortality rates among U.S. counties, cancer deaths are surging in some counties, even though overall cancer death rates dropped about 20% during that 34-year period.

Cancer mortality rates have declined in the U.S. in recent decades; however, major differences in cancer mortality still exist. What we learned in the recent analysis is the risk of death from prostate and other cancers may depend on where you live.

  • The researchers found that more than 19.5 million Americans died of cancer between 1980 and 2014. Of these, more than 1 million men died due to prostate cancer. Lung cancer killed more people in the U.S. than prostate or any other cancer.
  • Although many counties (1,558) had significant declines in prostate cancer death rates, percentage changes in male mortality rates between 1980 and 2014 ranged from a 69.4% decrease in Aleutians East Borough, and Aleutians West Census Area, Alaska, to a 26.1% increase in the mortality rate in Owsley County, Ky.
  • Researchers found the highest death rates from prostate cancer were in groups of counties in Mississippi, Alabama, Georgia, South Carolina, and Virginia. Counties in southern Florida and states along the U.S. border with Mexico had lower prostate cancer death rates.
  • Specifically, the highest death rate from prostate cancer in 2014 was in Madison County, Miss., with 64 deaths per 100,000 residents, followed by Macon County, Ala., with 57 deaths per 100,000 people, Wilcox County, Ala., with 55 deaths per 100,000 people, Phillips County, Ark., and Perry County, Ala., both with 54 deaths per 100,000 people.
  • The lowest death rate from prostate cancer was in Summit County, Colo., (10 deaths per 100,000 people), followed by Aleutians East Borough, Aleutians West Census Area, Alaska (11 deaths per 100,000 people) and Pitkin County, Colo., (13 deaths per 100,000 people).

To learn more and understand the research and data read the full article at Prostate Cancer News Today.



Boost Your Prostate Health!

It’s never to late to boost your prostate health! This great guide will get you started!!


Gene-regulator Therapy Could Help Keep Prostate Cancer from Spreading, Study Says

dna strand

Recently, researchers at Roswell Park Cancer Institute have found a naturally occurring molecule that limits the invasive capacity of prostate cancer.  This suggests that cancer could be prevented from spreading by treating patients with a man-made version of the factor. Using both animals and humans in their work, they screened for the molecule, miR-141. A microRNA (miRNA) that helps control gene activity.

Excerpt from reference article-
To their surprise, they found only a few miRNAs in lower levels than normal. When they manipulated the cells to produce more of the missing factors, miR-141 was the only one that could prevent cancer growth. Testing the molecule in a number of prostate cancer models, the team showed the factor also prevented metastases.

“This study represents the most comprehensive investigation to date of the role of the miR-141 molecule in regulating prostate cancer stem cells and their role in metastasis,” Dean Tang, PhD, chair of the Department of Pharmacology and Therapeutics at Roswell and senior author of the study, said in a press release.

“These preliminary findings suggest that miR-141 may suppress the metastatic cascade at an early stage and that the overexpression of miR-141 in prostate cancer cells results in less metastasis. Our observations provide a rationale for developing these targeted miRNA molecules into novel antitumor and antimetastasis replacement therapies.”

The study, published in the journal  Nature Communications can be found here, “MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes,”

The U.S. Preventative Services Task Force has reevaluated their stance on screening for prostate cancer and has released updated recommendations.

WEB ONLY iStock_000008787577SmallIn 2012, the task force recommended against routinely checking the levels of prostate-specific antigen, or PSA, in the blood, saying that the risks outweighed the rewards. But the latest draft loosens the reins for men 55 to 69 with no symptoms or history of prostate cancer: The former D rating, which discourages screening, has been upgraded to a C, which leaves the decision up to “a man’s values and preferences,” the task force said in a statement.

MEN 55 to 69 years

The decision about whether to be screened for prostate cancer should be an individual one. The USPSTF recommends that clinicians inform men ages 55 to 69 years about the potential benefits and harms of prostate-specific antigen (PSA)–based screening for prostate cancer. Screening offers a small potential benefit of reducing the chance of dying of prostate cancer. However, many men will experience potential harms of screening, including false-positive results that require additional workup, overdiagnosis and overtreatment, and treatment complications such as incontinence and impotence. The USPSTF recommends individualized decisionmaking about screening for prostate cancer after discussion with a clinician, so that each man has an opportunity to understand the potential benefits and harms of screening and to incorporate his values and preferences into his decision.

MEN 70 & older

The USPSTF recommends against PSA-based screening for prostate cancer in men age 70 years and older.

Dr. Vipul Patel is Awarded the B.C. Roy Eminent Medical Person Award

Patel awardIf you follow us, you know that our founder Dr. Vipul Patel is out to change the world!! Not only does he do amazing work here in the United States, but he is also always traveling the world to educate and train other physicians and patients.  IMG_4095IMG_4097

Dr. Vipul Patel has been awarded the B.C. Roy Eminent Medical Person Award, the highest honor any medical professional in India can receive. This award was instituted in 1976 in memory of B.C. Roy by the Medical Council of India. The Award is given annually in each of the following categories: Statesmanship of the Highest Order in India, Medical man-cum-Statesman, Eminent Medical Person, Eminent person in Philosophy, Eminent person in Science and Eminent person in Arts. This award was presented to Dr. Patel in March of 2017 by the President of India, and the Prime Minister was also on hand to offer his Congratulations.

Innovation in Cancer Detection


One of our primary goals here at the International Prostate Cancer Foundation is to be on the forefront of both research and education. Which mean we are always looking to the newest innovations in prostate cancer research and treatment. This year there have been many strides made in cancer detection. These are just a few of some of the amazing advancements moving the cause forward.

Prostate cancer detection from urine RNA steps closer
(excerpts from: http://www.medicalnewstoday.com/articles/307845.php)

Testing for non-coding RNA molecules in urine may offer a way to detect prostate cancer that is more accurate and reliable than current methods using biomarkers such as PSA and PCA3.

This was the conclusion of a German study presented at the European Association of Urology Congress (EAU16) in Munich, Germany, March 11-15, 2016.

Friedemann Horn, a professor in the University of Leipzig and the Fraunhofer Institute for Cell Therapy and Immunology IZI, and Manfred Wirth, a professor in the University of Dresden – both in Germany – led the work.

Prof. Wirth says:

“Our work on RNAs [ribonucleic acid] is allowing us to design a completely new kind of prostate cancer test.”

Current biomarker tests for prostate cancer measure levels of PSA (prostate-specific antigen) and PCA3 (prostate cancer gene 3), but they are not particularly accurate and can either miss many cancers or produce false positives.

FDA approves new diagnostic imaging agent to detect recurrent prostate cancer
(excerpts from: http://www.medicalnewstoday.com/releases/310654.php )

The U.S. Food and Drug Administration has approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment.

Prostate cancer is the second leading cause of death from cancer in U.S. men. In patients with suspected cancer recurrence after primary treatment, accurate staging is an important objective in improving management and outcomes.

“Imaging tests are not able to determine the location of the recurrent prostate cancer when the PSA is at very low levels,” said Libero Marzella, M.D., Ph.D., director of the Division of Medical Imaging Products in the FDA’s Center for Drug Evaluation and Research. “Axumin is shown to provide another accurate imaging approach for these patients.”

Two studies evaluated the safety and efficacy of Axumin for imaging prostate cancer in patients with recurrent disease. The first compared 105 Axumin scans in men with suspected recurrence of prostate cancer to the histopathology (the study of tissue changes caused by disease) obtained by prostate biopsy and by biopsies of suspicious imaged lesions. Radiologists onsite read the scans initially; subsequently, three independent radiologists read the same scans in a blinded study.

The second study evaluated the agreement between 96 Axumin and C11 choline (an approved PET scan imaging test) scans in patients with median PSA values of 1.44 ng/mL. Radiologists on-site read the scans, and the same three independent radiologists who read the scans in the first study read the Axumin scans in this second blinded study. The results of the independent scan readings were generally consistent with one another, and confirmed the results of the onsite scan readings. Both studies supported the safety and efficacy of Axumin for imaging prostate cancer in men with elevated PSA levels following prior treatment.

New device developed at UBC could improve cancer detection
(excerpts from: http://www.medicalnewstoday.com/releases/310195.php)

A new UBC-developed method to isolate cancer cells that have escaped from a tumour could soon pave the way for improved diagnosis and treatment.

The simple process involves a special device that squeezes cells in a blood sample through tiny funnels, which drive the cancer cells and blood cells into separate streams based on differences in their size and softness.

“Circulating tumour cells–cells from a tumour that have escaped into the bloodstream with the potential to spread into other tissues–are extremely useful for assessing a patient’s disease in order to select the most appropriate treatment,” said UBC mechanical engineering professor Hongshen Ma, the lead researcher. “These cells are particularly important for prostate cancer, where the site of metastasis is typically in the bone, where biopsies are difficult or impossible.”

Ma’s research focus is microfluidics, the flow of liquids through channels smaller than a human hair. The microfluidic device designed by his team captures cells based on their distinct internal structure–a mechanical analysis instead of the blood chemistry analysis used in conventional medical diagnostic techniques.

The device was first tested using blood samples spiked with cancer cells. It was then used to analyze blood samples from 20 patients with metastatic castration-resistant prostate cancer, an advanced form of cancer, and from four healthy individuals.

Robot Technology Aids in Education

Dr Alejandro Granados from Imperial College London demonstrates the robotic rectum technology,.jpg

Dr Alejandro Granados from Imperial College London demonstrates
the robotic rectum technology

Excerpts from Medical News Today contained below.

Technology seems to be moving at lightening speed these days. From computers that fit in our hand, to robotic learning tools. It’s a progressive time in our history.  This past July, scientists at Imperial College London developed a prosthetic buttocks and rectum to help train doctors and nurses to perform prostate cancer exams.

The idea is the device helps train doctors and nurses to perform rectal examinations by accurately recreating the feel of a rectum, as well as providing feedback on their examination technique. The device contains small robotic arms that apply pressure to the silicone rectum, to recreate the shape and feel of the back passage.

Rectal examinations are necessary to diagnose conditions such as prostate cancer and involve a medic placing their index finger into the anus, and feeling the prostate gland.


Generally, cancerous prostates tend to feel hard and knobbly, but learning exactly what a potentially cancerous prostate feels like can be difficult, explains Dr Fernando Bello, from the Department of Surgery and Cancer at Imperial College London: “Internal examinations are really challenging to learn – and to teach. Because the examinations occur in the body, the trainer cannot see what the trainee is doing, and vice versa. In addition to this, medics rarely get the chance to practise the examination, as few patients would volunteer as practice subjects. In fact there is only one person registered in the country as a test subject, called a Rectal Teaching Assistant (RTA) in the UK.

“But the results of these examinations can have major implications for patients – they are very important for early diagnosis of various conditions such as prostate cancer.”

Although plastic models exist to help train medical staff, these do not feel like living flesh and tissue, added Dr Bello. Therefore to help doctors and nurses practice how to perform these examinations – and to ensure they are as comfortable as possible for patients, Dr Bello and his team have created a robotic ‘trainer rectum’.

When using the trainer, a doctor inserts his finger inside a silicone thimble attached to robotic technology able to recreate the exact sensation of the human rectum.

Furthermore, a computer screen behind the device can display a 3D model of the rectum and prostate, allowing the doctor, with the aid of 3D glasses, to see the anatomy while they perform the examination. The technology can be programmed for different scenarios, allowing the anatomy to be changed each time, explained Dr Alejandro Granados, also from the Department of Surgery and Cancer at Imperial and who is leading the development of the robotic rectum.

He added: “We have already asked a number of doctors and nurses – including prostate specialists and cancer surgeons – to trial the technology. They commented on the great advantage of being able to alter the anatomy. The size and shape of the rectum and prostate can vary greatly from person to person, and this technology enables medics to practice their skills in many different virtual patients. They also observed that because these examinations are performed solely by feel, experiencing a realistic sensation is crucial.”

Furthermore, the team are continuing to perfect the device, by collecting data from real prostate examinations in patients.

To read the full article at Medical News Today click here.

The Legacy of a Legend…Farewell, Mr. Palmer

Screen Shot 2016-10-18 at 1.09.50 PM.png

image courtesy of arniesarmy.org

Recently, golf legend, Arnold Palmer passed away. We’re all aware of the legacy of golf achievements the man left. Over 9o championships, in addition to 18 wins in foreign championships and 12 wins on the senior tour he was not only a force on the golf course, but in the community of cancer research and treatment.

This is a less well-known part of Arnold’s history, as he was more concerned with moving the cause forward than personal notority. At age 67 in 1997, Arnold had a PSA screening test for prostate cancer. His PSA had been rising for 2-3 years and had resulted in 2 prior normal prostate biopsies. But this time, his third biopsy showed him to have prostate cancer. He went to Mayo clinic where the doctors discussed the treatment options. Wanting the highest chance for cure, Arnold opted for surgery to remove his prostate. The findings showed enough risk for possible recurrence that he then received 7 weeks of radiation therapy. Remarkably, only 6 weeks later, after physical therapy, Arnold was back on the golf course competing in tournaments.

He won the admiration of his fans (known as Arnie’s Army) and all Americans by becoming a lifelong spokesperson for prostate cancer control. He advocated prostate cancer screening with PSA. Regarding screening, and in keeping with current recommendations, he felt that men’s lives would be better if they just talked to their doctor about it. “That’s health and living”, he said, and felt that being healthy is the “good life”.

Arnold also formed the Arnold Palmer Prostate Center in Palm Springs at the Eisenhower Lucy Curie Cancer Center, and then supported the Arnold Palmer Pavilion at U. Pittsburgh Medical Center and Latrobe Area Hospital. Because of his advocacy, many more men have been cured of prostate cancer and are survivors.